Biznesradar bez reklam? Sprawdź BR Plus

Podatki

  • Prelude Therapeutics (PRLD) Q4 Loss Widens 616.7% to $1.29/Share as Revenue Climbs to $12.1M

    Prelude Therapeutics reports Q4 loss of $1.29/share, 616.7% wider than expected, despite revenue jumping to $12.1M from $6.5M sequentially. The post Prelude Therapeutics (PRLD) Q4 Loss Widens 616.7% to $1.29/Share as Revenue Climbs to $12.1M first appeared on Alphastreet.

    AlphaStreet AlphaStreet 2026-03-10, 14:35

  • Yalla Group (YALA) Q4 Earnings Flat at $0.21 EPS, $83.9M Revenue Signals Growth Stall

    Yalla Group's Q4 adjusted EPS of $0.21 and revenue of $83.9M matched the prior quarter exactly, signaling a growth plateau. The post Yalla Group (YALA) Q4 Earnings Flat at $0.21 EPS, $83.9M Revenue Signals Growth Stall first appeared on Alphastreet.

    AlphaStreet AlphaStreet 2026-03-10, 13:41

  • Yalla Group (YALA) Reports Q4 EPS of $0.20 as Revenue Stalls at $83.9M

    Yalla Group reports Q4 adjusted EPS of $0.21 on flat sequential revenue of $83.9M, maintaining profitability but showing zero growth. The post Yalla Group (YALA) Reports Q4 EPS of $0.20 as Revenue Stalls at $83.9M first appeared on Alphastreet.

    AlphaStreet AlphaStreet 2026-03-10, 13:43

  • FuelCell Energy (FCEL) Q1 Loss Narrows to $0.52/Share vs $0.68 Estimate, Revenue Misses by 29.5%

    FuelCell Energy narrows Q1 loss to $0.52/share vs $0.68 estimate, but revenue of $30.5M misses $43.3M consensus by 29.5% on module timing. The post FuelCell Energy (FCEL) Q1 Loss Narrows to $0.52/Share vs $0.68 Estimate, Revenue Misses by 29.5% first appeared on Alphastreet.

    AlphaStreet AlphaStreet 2026-03-10, 13:43

  • BETA Technologies (BETA) Reports Wider Q4 Loss But Forecasts Triple-Digit Revenue Growth for 2026

    BETA Technologies reported Q4 loss of $1.71/share vs expected $0.47 loss; revenue $32.1M; guides 2026 revenue $130M-$135M, up 265% year-over-year. The post BETA Technologies (BETA) Reports Wider Q4 Loss But Forecasts Triple-Digit Revenue Growth for 2026 first appeared on Alphastreet.

    AlphaStreet AlphaStreet 2026-03-10, 13:59

  • Yext (YEXT) Q4 Earnings: $0.15 EPS as Revenue Flatlines at $112M

    Yext reports Q4 adjusted EPS of $0.15, matching prior quarter, as revenue stalls at $112M year-over-year. The post Yext (YEXT) Q4 Earnings: $0.15 EPS as Revenue Flatlines at $112M first appeared on Alphastreet.

    AlphaStreet AlphaStreet 2026-03-10, 13:31

  • FuelCell Energy (FCEL) Q1 Loss Narrows to $0.52/Share vs $0.68 Estimate; Revenue Misses by 30%

    FuelCell Energy narrows Q1 loss to $0.52/share vs $0.68 estimate, but revenue of $30.5M misses $43.3M consensus by 30% on timing delays. The post FuelCell Energy (FCEL) Q1 Loss Narrows to $0.52/Share vs $0.68 Estimate; Revenue Misses by 30% first appeared on Alphastreet.

    AlphaStreet AlphaStreet 2026-03-10, 13:33

  • Legend Biotech Q4 2025 Earnings Results

    Legend Biotech (NASDAQ: LEGN) reported financial results for the fourth quarter and full year ended December 31, 2025, highlighting continued... The post Legend Biotech Q4 2025 Earnings Results first appeared on Alphastreet.

    AlphaStreet AlphaStreet 2026-03-10, 12:48

  • ABM Industries Q1 FY26 Earnings Results

    ABM Industries (NYSE: ABM) reported financial results for the first quarter of fiscal 2026, delivering solid revenue growth driven by... The post ABM Industries Q1 FY26 Earnings Results first appeared on Alphastreet.

    AlphaStreet AlphaStreet 2026-03-10, 12:56

  • Unusual Machines Q4 FY25 Earnings Results

    Revenue Performance Unusual Machines reported robust top-line expansion for the fourth quarter and full year ended December 31, 2025. Full-year... The post Unusual Machines Q4 FY25 Earnings Results first appeared on Alphastreet.

    AlphaStreet AlphaStreet 2026-03-10, 12:07

  • ACCO Brands Q4 FY25 Earnings Results

    Revenue Performance ACCO Brands Corporation reported full-year 2025 net sales of $1.525 billion, representing an 8.5 percent decline from the... The post ACCO Brands Q4 FY25 Earnings Results first appeared on Alphastreet.

    AlphaStreet AlphaStreet 2026-03-10, 12:14

  • U.S. Regulators Turn Up the Heat on Big Tech Acquisitions

    TL;DR: Washington is tightening the screws on tech M&A, and the message from regulators is clear: the era of Big... The post U.S. Regulators Turn Up the Heat on Big Tech Acquisitions first appeared on Alphastreet.

    AlphaStreet AlphaStreet 2026-03-10, 12:16

  • Sharplink Q4 FY25 Earnings Results

    Revenue Growth and Net Income Metrics Sharplink posted substantial top-line expansion for the full year ended December 31, 2025, recording... The post Sharplink Q4 FY25 Earnings Results first appeared on Alphastreet.

    AlphaStreet AlphaStreet 2026-03-10, 12:21

  • ARS Pharmaceuticals Q4 FY25 Earnings Results

    Revenue Performance ARS Pharmaceuticals recorded total revenue of $28.1 million for the fourth quarter of 2025, driven largely by $20.3... The post ARS Pharmaceuticals Q4 FY25 Earnings Results first appeared on Alphastreet.

    AlphaStreet AlphaStreet 2026-03-10, 12:27

  • Kohl’s Corporation Q4 FY25 Earnings Results

    Revenue Performance Kohl’s Corporation reported a decline in top-line results for both the fourth quarter and the full fiscal year... The post Kohl’s Corporation Q4 FY25 Earnings Results first appeared on Alphastreet.

    AlphaStreet AlphaStreet 2026-03-10, 12:35

  • Repay (RPAY) Reports $0.24 Adjusted EPS on $77.7M Revenue, Posts $6.6M GAAP Loss

    Repay posts $0.24 adjusted EPS on flat $77.7M revenue, with GAAP loss of $6.6M highlighting profitability adjustments ahead of tonight's call. The post Repay (RPAY) Reports $0.24 Adjusted EPS on $77.7M Revenue, Posts $6.6M GAAP Loss first appeared on test.

    AlphaStreet AlphaStreet 2026-03-09, 21:11

  • RNAC CEO Carsten Brunn Sells 23,766 Shares at $6.82, Retains 323,530 Shares

    CEO Carsten Brunn sold 23,766 shares at $6.82 per share, totaling $162,077, while retaining 323,530 shares. The post RNAC CEO Carsten Brunn Sells 23,766 Shares at $6.82, Retains 323,530 Shares first appeared on test.

    AlphaStreet AlphaStreet 2026-03-09, 21:12

  • Korn Ferry (KFY) Q3 Earnings Beat: EPS Rises 7.6% to $1.28 on 7.2% Revenue Growth

    Korn Ferry posted Q3 adjusted EPS of $1.28, down 7.6% year-over-year, as revenue of $725M rose 7.2% but slipped sequentially. The post Korn Ferry (KFY) Q3 Earnings Beat: EPS Rises 7.6% to $1.28 on 7.2% Revenue Growth first appeared on test.

    AlphaStreet AlphaStreet 2026-03-09, 21:14

  • Boundless Bio (BOLD) Posts First Revenue of $17.3M, Narrows Q4 Loss to $0.58/Share

    Boundless Bio narrows Q4 loss to $0.58/share and posts first-ever revenue of $17.3M, guiding to $78-80M for 2026. The post Boundless Bio (BOLD) Posts First Revenue of $17.3M, Narrows Q4 Loss to $0.58/Share first appeared on test.

    AlphaStreet AlphaStreet 2026-03-09, 21:24

  • CMCT Reports Q4 Loss of $11.20/Share

    CMCT reports Q4 loss of $11.20/share, matching prior quarter but widening sharply from $0.37/share year-ago loss. The post CMCT Reports Q4 Loss of $11.20/Share first appeared on test.

    AlphaStreet AlphaStreet 2026-03-09, 20:31

  • Vicor (VICR) reported Q4 2025 diluted EPS of $1.01

    Vicor's Q4 EPS of $1.10 crushed the $0.48 estimate, yet shares dropped 10.6% as revenue surged 310% sequentially to $452.7M. The post Vicor (VICR) reported Q4 2025 diluted EPS of $1.01 first appeared on test.

    AlphaStreet AlphaStreet 2026-03-09, 19:42

  • BREAKING: KFY Reports Q3 Earnings

    Korn Ferry posts Q3 adjusted EPS of $1.28 on revenue of $725M. The post BREAKING: KFY Reports Q3 Earnings first appeared on test.

    AlphaStreet AlphaStreet 2026-03-09, 19:52

  • ACCO Brands adjusted earnings per share of $0.38 for Q4 2025

    ACCO Brands posts Q4 adjusted EPS of $0.38, flat sequentially but down 2.6% year-over-year, as revenue declines 4.3% to $428.8 million. The post ACCO Brands adjusted earnings per share of $0.38 for Q4 2025 first appeared on test.

    AlphaStreet AlphaStreet 2026-03-09, 20:02

  • ARS Pharmaceuticals (SPRY) Posts Q4 Loss of $0.42/Share as Revenue Jumps 332% YoY to $28.1M

    ARS Pharmaceuticals reports Q4 loss of $0.42/share as revenue surges 332% YoY to $28.1M despite sequential decline from Q3 peak. The post ARS Pharmaceuticals (SPRY) Posts Q4 Loss of $0.42/Share as Revenue Jumps 332% YoY to $28.1M first appeared on test.

    AlphaStreet AlphaStreet 2026-03-09, 18:12

  • VIAV Shares Plunge 10% Despite Beating Q4 EPS Estimates by 17% on Profitability Concerns

    VIAV posts Q4 EPS of $0.22, beating estimates by 17%, but shares drop 10% as investors weigh profitability challenges against sequential revenue growth. The post VIAV Shares Plunge 10% Despite Beating Q4 EPS Estimates by 17% on Profitability Concerns first appeared on test.

    AlphaStreet AlphaStreet 2026-03-09, 18:13
Biznesradar bez reklam? Sprawdź BR Plus